试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-05
Induction Optimization With Stelara for Crohn's Disease
编号:NCT04629196登记状态:提前终止企业 / 申办者:NYU Langone Health
药物 / 成分:Ustekinumab、Ustekinumab、Ustekinumab
登记的停止原因(原文):Other effective drugs have been introduced to market since the beginning of the study.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-05
Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)
编号:NCT04989218登记状态:提前终止企业 / 申办者:University of Alabama at Birmingham
药物 / 成分:Novel combination of chemotherapy and immunotherapy
登记的停止原因(原文):Slow accrual and study sponsor decision.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-05
A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction
编号:NCT05510245登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:PF-07081532
登记的停止原因(原文):The decision to terminate clinical development of lotiglipron is based on pharmacokinetic data from Phase 1 drug-drug-interaction studies and laboratory measurements of elevated transaminases in these Phase 1 studies as well as a Phase 2 study.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-04
Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer
编号:NCT04294784登记状态:提前终止企业 / 申办者:Huazhong University of Science and Technology
药物 / 成分:Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)、Albumin-bound Paclitaxel
登记的停止原因(原文):slow recruitment forcing early suspension of screening and enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-04
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
编号:NCT04493619登记状态:提前终止企业 / 申办者:Opna Bio LLC
药物 / 成分:PLX2853、Carboplatin
登记的停止原因(原文):study terminated due to business realignment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-04
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
编号:NCT04745832登记状态:提前终止企业 / 申办者:MEI Pharma, Inc.
药物 / 成分:Zandelisib、Rituximab、Bendamustine、CHOP
登记的停止原因(原文):Discontinuation of zandelisib program
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-04
Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
编号:NCT04795713登记状态:提前终止企业 / 申办者:Molecular Templates, Inc.
药物 / 成分:MT-6402
登记的停止原因(原文):Terminated by Sponsor
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-04
Effectiveness of Periocular Drug Injection in CATaract Surgery
编号:NCT05158699登记状态:提前终止企业 / 申办者:Luigi Rondas
药物 / 成分:Bromfenac、Dexamethasone、Triamcinolone Acetonide、Ketorolac-Phenylephrine Ophthalmic 0.3%-1% Intraocular Solution
登记的停止原因(原文):Results of interim analysis: stop the trial due to one group being significantly different from the other three groups. Furthermore, shortage of study medication.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-04
ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases
编号:NCT05265013登记状态:提前终止企业 / 申办者:Rakuten Medical, Inc.
药物 / 成分:ASP-1929 Photoimmunotherapy、pembrolizumab
登记的停止原因(原文):Business decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-01
A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients
编号:NCT01371344登记状态:提前终止企业 / 申办者:Astellas Pharma Europe Ltd.
药物 / 成分:Tacrolimus granules、Tacrolimus capsules
登记的停止原因(原文):Trial will not complete until at least 2025 and evolution of immunosuppressant therapy has made it unlikely that patients will convert from Modigraf to Prograf.
查看官方原始记录 ↗